D
URING 2012, the next generation sequencing (NGS) has attracted large attention in the biomedical research community especially for personalized medicine. Also, the third generation sequencing has become available. Thus, the state-of-art sequencing technology and analysis are being reviewed in this year's Bioinformatics spotlight.
Next-generation sequencing (NGS) is high-throughput nucleic acid sequencing technology with wide dynamic range and single base resolution. The full promise of NGS depends on the optimization of NGS platforms, sequence alignment and assembly algorithms, data analytics, novel algorithms for integrating NGS data with existing genomic, proteomic, or metabolomic data, and quantitative assessment of NGS technology in comparing to more established technologies such as microarrays. NGS technology has been predicated to become a cornerstone of personalized medicine.
II. SEQUENCE APPLICATIONS
Sequencing technologies have been utilized in popular biomedical applications such as epigenome, interactome, and cytogenome. Epigenome plays an important role in cell differentiation. Epigenetic control includes methylation of DNA, small RNA, and protein binding etc, and occurs transcriptionally and post-transcriptionally. With the same base pair sequence, the epigenetic control of DNA and RNA may result in different gene expression. Because epigenetic changes occur early in the disease process and are detectable in serum, they can be used as the therapeutic targets and diagnostic biomarkers for studying disease progression and mechanism. NGS can identify the epigenetic markers and the resulting change in expression level on a genome-wide basis. Interactome is to investigate protein interactions with nucleic acids. For instance, chromatin immuno-precipitation (CHiP) determines the location of DNA binding sites on the genome for particular DNA binding proteins such as transcription factors, polymerases, nucleases, and histones. It uses antibodies to select specific binding proteins that are intentionally cross-linked to DNA binding sites, and the DNA strand can identify the sequence.
In cytogenome, in addition to single nucleotide polymorphisms (SNPs), sequencing technology can study aberrations in chromosomal structure including inherited or somatically acquired copy number variation, large structural rearrangements, and aneuploidy linked with disease.
III. NEXT GENERATION SEQUENCING
Comparing to the first-generation high-throughput Sanger sequencing, the NGS technology allows sequencing to be done at a much higher speed with greater throughput and dynamic range. It can achieve single base resolution at a targeted or whole genome/transcriptome level in a single run. NGS can measure gene expression levels based on the order of the nucleotides in a manner similar to serial analysis of gene expression (SAGE) (i.e., sequence reads are turned into an expression quantity by counting the number of reads that align to or "hit" a feature in the reference sequence).
The current widely adopted commercially available NGS platforms are Illunima HiSeq system (1000/2000), Roche/454 FLX+ system, ABI/SOLiD (5500 Series), and Helicos HeliScope system. These platforms differ primarily in experimental protocol, but share similar sequencing steps. After library preparation, DNA fragments are isolated and attached to a substrate. These fragments are amplified and then sequenced in parallel. The parallel iterative sequencing steps in parallel produce a massive set of fluorescence or luminescence image data, which are turned into sequence reads by platform specialized base calling software.
Illumina platform utilizes sequencing by synthesis (SBS) technology, and is the most widely applied sequencing platform in the current market [1] . Reversible terminator detects nucleotide sequences and is cyclic where nucleotides with dyes are first incorporated, and then dyes are washed away after the laser excitation and imaging steps. This technology is highly parallel and permitting the formation of hundreds of millions of spatially separated clusters in one flowcell.
Roche 454 pyrosequencing technology is the oldest in NGS derived from Sanger sequencing that uses chain termination with dideoxynucleotide. In comparison, the pyrosequencing detects the pyrophosphate released with the addition of a nucleotide. With a single type of deoxy nucleotide-tri phosphate (dNTP) is added per cycle to all the PicoTiterPlace (PTP) wells, a series of pyrosequencing enzymatic reactions [2] leads to the bioluminescence generation, which is recorded by a high resolution camera. Through cyclic and repeated addition of each type of dNTP, the sequence is identified.
While the above two sequencing technologies are based on polymerase mode of chain extension, the SOLiD [3] technology uses DNA ligase. In ligation, we modify the 3' end of the template to allow the bead to covalently attach to a glass slide and to carry out the reactions of ligation, detection, and cleavage in a cyclic manner until the entire length of the template is covered. The SOLiD sequencing is highly accurate.
Helicos true single molecule sequencing (tSMS) technology directly sequences single molecules of DNA or RNA with no amplification step involved. tSMS and DRS (Direct RNA Sequencing) simultaneously sequence of large numbers of strands of single DNA or RNA molecules by using a proprietary form of sequencing-by-synthesis, where labeled bases are sequentially added to the nucleic acid templates captured on a flow cell [4] .
Currently, the cost and the read length are still challenges for NGS. Ten years ago, sequencing an entire human genome costs several million dollars. The next generation sequencing has brought the cost down to a couple of thousands, which has not reached the goal set in 2004 NIH Roadmap to sequence an entire human genome less than $1000. On read length, for Illumina and SOLiD platforms can produce 100-base reads. To address this challenge, they develop paired-end sequencing technology to increase the reliability. The 454 platform has longer read length, but it is still in the scale of hundreds of base pairs per read. Thus, there is need for revolutionary solution.
IV. THE THIRD GENERATION SEQUENCING
The third-generation sequencing technologies are emerging to reduce the cost and to increase the read length. They include Oxford Nanopore GridION system, Pacific Biosciences PacBio RS system, and Life Technologies Ion Proton system. The Oxford Nanopore technology was first proposed in the mid-1990s in Oxford, Harvard, and UCSC, with the company founded in 2005. There are two classes of nanopore. Biological nanopore uses protein (e.g., a pore-forming protein in a lipid bilayer membrane) and solid-state nanopore uses synthetic material (e.g., silicon nitride or graphene).
Pacific Biosciences PacBio RC system is also called real time sequencing because the sequencing process is continuous. There are no wash steps or reversible terminators. The phosphor-linked nucleotides are being added to the primer strand via epifluorescense detection. A fluorescence pulse is recorded in real time as the phosphor-linked nucleotide is present in the zero-mode waveguide (ZMW) detection zone [5] soon after the dye-labeled pentaphosphate byproduct quickly diffuses away. Multiple fold sequencing can be used to achieve more than 99% accuracy [6] .
Life Technologies Ion Proton Torrent system leverages Moore's Law in manufacturing semiconductors to sequence genomes without an optical device. The integrated circuit contains large array of sensors, with each a single floating gate connected to an underlying ion-sensitive field effect transistor. Like sequencing by synthesis, the nucleotides are detected by the hydrolysis reaction that takes place during base incorporation and releases a proton for every base added [7] .
Because of the cost for sequencing a genome keeps decreasing, personalized genomics becomes feasible. Sequencing platform vendors have developed several small-scale sequencers for personalized usage such as Illumina MySeq system, Roche/454 GS Junior system, and Life Technologies Ion PGM system etc. [8] V. THE SEQUENCING BIOINFORMATICS PIPELINE RNA-Seq is a branch of NGS that can be used to quantify expression levels of gene, transcript, exon, and miRNA. The typical RNA-Seq data analysis pipeline includes: 1) cleaning data for quality control; 2) mapping the short reads to reference genome or transcriptome; 3) quantifying expression levels of genes or other genomic features (e.g., isoforms, exons, junctions); 4) normalizing expression levels among samples or replicates; 5) identifying differentially expressed genomic features (i.e., biomarkers) between two conditions; and 6) validating the potential biomarkers in the context of biomedical applications. During the last few years, analyzing RNA-Seq data with efficiency and accuracy has become increasingly active.
A. Quality Control
The NGS technology provides DNA or RNA sequence information in single-base resolution. Although it has higher accuracy in comparing to hybridization-based technologies, the errors or biases in sequencing runs can still propagate to the downstream analyses. Thus, after transcriptome sequencing and be-fore feeding sequencing data into analysis pipeline, quality control step is needed to avoid garbage-in-garbage-out situation.
NGS read length varies. Some platforms (Illumina, SOLiD) allow the selection of desired but fixed read length per run, while others (Roche 454 and Helicos) offer variable length reads. On one hand, to identify nucleotides in a sequence read, base calling error increases in proportion to length. On the other hand, to map sequenced reads to a specified genome, mapping accuracy increases with read length. Thus, size and base composition of the genome of interest must be considered to maximize the number of unambiguous reads. The quality control step filters out low-quality short sequencing reads based on several predefined metrics. NGS image analysis (intensity, background and noise) software will get base calling and quality scores. Basecalling quality is the most intuitive metric to judge the fineness of a read. Short sequencing reads should either be discarded if the average base pair quality is lower than a threshold, or be trimmed if a portion of reads have extremely low base pair qualities. Several tools such as NGSQC, PRINSEQ, RNA-SeQC, and RSeQC provide information such as per base quality score distribution, per base nucleotide frequency, reads GC-content distribution, percent of duplicate reads, and read length distribution using raw sequencing reads. They also provide after-mapping information such as per base coverage of genes and fragment length distribution for paired-end sequencing. In addition, the provide good visualization interface for users to examine the quality of their sequencing samples [9] - [12] .
In general, the QC step is not platform-dependent. The same metrics can be applied to sequencing data generated by all major platforms. Even though the concept is easy to understand and implement, deciding a threshold for filtering is nontrivial. For example, base-calling quality is a pretty common metric to assess the quality of a read. However, the cut-off quality value to trim or remove a read before downstream analysis is data-dependent. There is no standard criterion until now that more research is needed.
B. Mapping
Short sequencing reads that pass the QC step are eligible to be mapped to the genome or transcriptome. The goal of the mapping is to produce the best alignment based on specified criteria while trying to align as many of the reads as possible. Read alignments may be analyzed and interpreted at genome, gene, and nucleotide levels. For instance, at the genome level, individual samples may be classified using differentially expressed genes to predict clinical outcomes. At the gene level, base content in terms of the proportion of purines/pyrimidines may reveal transcriptional and translational markers. At the nucleotide level, mutations such as insertions/deletions (indels) and single nucleotide polymorphisms (SNPs) may point to basic disease mechanisms. Consequently, the level of analysis and interpretation is driven by the application of interest.
For the alignment step, different platforms have different reads reporting format. For example, Illumina provides reads with fixed read length, ABI/SOLiD provides reads in color space with fixed read length, and Roche/454 provides reads with variable read lengths. Thus, most of the mappers work well with 1) the targeted sequencing platform; 2) paired-end reads support; 3) multi-threading support; 4) gzip support; 5) multi-hit reporting support; and 6) a comprehensive reporting in SAM/BAM format [13] . Because sequence mapping is a computationally intensive job, CPU clusters, the GPU computing, or cloud computing are needed [14] .
Sequence mapping is a similarity search but in an extremely large scale. The traditional Smith-Waterman or Needleman-Wunsch similarity search algorithms are not capable of handling such huge data. A mapper needs to be fast and memory-efficient, while maintaining high accuracy and low false positive, most of fast mapping algorithms utilize indices constructed from the read sequences, or the reference sequence, or sometimes both. Thus, the mapping algorithms can be grouped based on the indexing methods such as hash tables (e.g., Novoalign, SHRiMP) or suffix trees (e.g., BWA, Bowtie) [15] . Or the mapping algorithms can be categorized based on read gap handling methods: ungapped alignment (e.g., Bowtie, mrsFAST), gapped alignment (e.g., Bowtie2, BWA), and spliced alignment (e.g., TopHat, OSA). The ungapped alignment does not allow insertions or deletions (indels) and has the lowest computational complexity that allows only matches and mismatches. The gapped alignment allows mismatches and indels within the reads, but indels are usually less than 10 base pairs long. For spliced alignment, because the algorithm reads into smaller segments before mapping, it is possible to handle a long insertion within reads (e.g., a long span across intronic region for a single read). For RNA-Seq data, there are also several possible alignment strategies such as directly aligning reads to genome only, or directly aligning reads to transcriptome only, or aligning reads to genome first and then aligning the rest of reads to transcriptome, and vice versa.
The alignment tools offer exclusive templates for genomic feature annotation. Reference genomes or whole genome templates (e.g., NCBI Human Genome Assembly Build 37.1, and UCSC Assembly HG19) have chromosome-by-chromosome of the organism genome (DNA), with emphasis on physical nucleotide location. Annotated templates (e.g., NCBI RefSeq, UCSC Known Genes, EBI Ensembl, and NCBI AceView) have curated references that annotate genes, introns, exons, and regions before being transcribed or translated. dbSNP NCBI, ASTD EBI, smirnaDB, TarBase consist primarily of genomic features such as microRNAs, known exon junctions, conserved domains, SNPs, and ESTs, and focus on specialized research topics. NCBI's RefSeq is considered a highly curated and reliably annotated template. NCBI AceView combines RefSeq annotations with transcript information from GenBank and dbEST.
C. Quantification
Estimating the expression abundances gives insight into cellular mechanisms [16] for applications such as personalized medicine, disease classification, and microbiological diagnosis in case of infection, etc. By just mapping the RNA-seq reads to the reference, we can identify major types of alternative splicing such as exon skipping, mutually exclusive exon, alternative donor/acceptor exon and intron retention [17] etc. to estimate the expression levels.
There are several ways in quantifying expression. The Naïve Count-Based Quantification includes ERANGE (Enhanced Read Analysis of Gene Expression) that sums up reads corresponding to exons as well as spliced junctions for each locus and then normalizes into expanded exonic read density by the predicted mRNA length [18] ; Normalization by Expected Uniquely Mappable Area (NEUMA) that pre-computes gene-level (all mRNA isoforms of a single gene exclusively) and mRNA isoform-level numbers of informative reads from an annotation model provided by the user or RefSeq [19] ; and the Jiang and Wong method that models the reads fall in the region of the genome annotated with multiple isoforms as a Poisson variable [20] .
The Linear Model-Based Quantification includes rQuant that simultaneously estimates the position biases and the abundance of RNA transcripts, then uses a linear model to correct this bias [21] ; Howard and Heber method that uses probabilistic model to estimate the ratio of isoforms in a transcript that takes into account the non-uniformity of read positions [22] ; and IsoInfer that makes use of exon-intron boundary, transcription start site (TSS) and poly-A site (PAS) information to calculate the expression levels from RNA-Seq reads [23] .
The Multinomial Model-Based Quantification includes MISO (Mixture of ISOforms) model that statistically estimates the expression of alternatively spliced exons to assess the confidence in these estimates, and offers functional insight into pre-mRNA processing [24] ; IsoEM that uses a modified expectation-maximization algorithm to estimate isoform and gene specific expression with much less computing time in comparing to similar tools [25] ; RSEM that uses an expectation-maximization-based model to quantify single-end and paired-end RNA-seq data, and maps reads to accurately quantify the expression levels [26] ; Cufflinks that estimates the abundance of assembled transcripts by implementing Dilworth's Theorem [27] , and is the most standard expression quantification tool for RNA-seq data; and Alexa-seq (Alternative expression by sequencing) that catalogs transcripts and assesses the alternative expression of known and predicted mRNA isoforms [28] .
Annotating and quantifying the complete set of transcripts remain as challenging tasks in biology because most of the existing quantifiers are based on the predefined transcript annotation. The isoform quantification results not only depend on quantification algorithm, but also depend on annotation completeness and accuracy. Thus, this is open research area for more investigation.
D. Normalization
After quantification step, raw counts need to be normalized before the expression analysis. Currently, most of the RNA-Seq normalization methods multiply or divide gene or isoform expressions of a given sample by a fixed factor such as RPKM (Reads Per Kilobase per Million mapped reads), RPM (Reads Per Million mapped reads), FPKM (Fragments Per Kilobase per Million mapped fragments), and FPM (Fragments Per Million mapped fragments). However, it has been shown that these methods are vulnerable to small value but highly differential expressed genes. To overcome the above issues, TMM (Trimmed Mean of M-values), TPM (Transcript Per Million transcripts), and VOOM (mean-variance modeling at the observational level) are proposed [29] . From the systematic comparison, these normalization methods are proven to be more robust and able to control the false-positive rate while maintaining the power to detect differentially expressed genes [30] .
E. Differential Expression
This step builds model to identify differentially expressed genes from the quantified RNA-Seq data. For instances, the package "edgeR" uses the negative binominal distribution to model the over dispersion in relative to the Poisson distribution for the digital gene expression data that has a small number of replicates, and then uses an exact test to compute the exact p-values. The adjusted p-values after multiple testing corrections are used to determine the significance of differential expression between conditions. Another package "DEGseq" uses the Poisson model with likelihood ratio test to model RNA sequencing as a random sampling process. A third package QuasiSeq extends the idea proposed in edgeR, and applies quasilikelihood, quasi-likelihood shrink and quasi-likelihood spline methods to quasi-Poisson or quasi-negative binomial models for identifying differentially expressed genes in RNA-Seq data.
Once the expressed genes are identified from RNA-Seq, then various bioinformatics and biostatics methods can be used to identify biomarkers with specific biomedical applications.
VI. THE ADVANTAGE OF NGS OVER MICROARRAY
In comparing to microarray, the established method of gene expression measurement, NGS RNA-Seq has several clear advantages. First, RNA-seq has no hybridization effects, which is of particular importance for detecting expression in low value range. The dynamic range of RNA-seq is three to four orders of magnitude, which is superior to microarray's two orders of magnitude. This allows the measurement of both the very low expressing and extremely high expressing genes beyond what microarrays can detect. Correlation has been found between microarray and RNA-seq [31] , [32] but correlation is higher in the mid range expressing genes, while RNA-Seq does better for high and low expressing genes [33] .
Second, on biomarker discovery, the sequence can be impartially assembled and not interrogated by a predetermined array probes. Thus, comparing to microarray, NGS expression detection and differentiation can discover novel genes or variants. Moreover, when characterizing both novel and known transcripts, the single base resolution of sequence offers greater precision than microarray.
Third, an invaluable feature of NGS over standard microarray is its whole "ome" capability and integratability. The data acquisition through whole genome option can prevent the bias introduced by the selection of areas to probe. Also, the whole genome, transcriptome, epigenome and interactome can be all covered by one sequencing platform at once. Thus, NGS not only allows valid statistical analysis on phenotype to genotype, but also, on a personalized medicine level, NGS may help identify the genetic elements regarding individual's susceptibility to disease, and responses to drug.
VII. THE FUTURE LOOK OF NGS
Looking forward to 2013, there exist many research opportunities for EMBS community. EMBS researchers not only can assist in developing The Third Generation Sequencer to continually increase sequencing speed, and data accuracy while reducing the cost, but also should contribute to data analytics. As the sequencing technology cost goes down, more and more data is becoming available. With a whole genome sequencing data size in tera-byte per person, and with next generation sequencing bioinformatics fall short during the last few years, the need and cost for analyzing these enormous amounts of sequencing data goes up exponentially. Thus, NGS is a promising field for motivated young researchers who are looking for opportunities in bioinformatics. 
